Literature DB >> 29222324

Pharmacologic agents to prevent and treat relapse after allogeneic hematopoietic cell transplantation.

Robert J Soiffer1,2,3, Yi-Bin Chen3,4.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 29222324      PMCID： PMC6142540          DOI： 10.1182/asheducation-2017.1.699

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN： 1520-4383


× No keyword cloud information.
  77 in total

1.  Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL).

Authors:  Barbara Wassmann; Heike Pfeifer; Michael Stadler; Martin Bornhaüser; Gesine Bug; Urban J Scheuring; Patrick Brück; Matthias Stelljes; Rainer Schwerdtfeger; Nadezda Basara; Jolanta Perz; Donald Bunjes; Georg Ledderose; Rolf Mahlberg; Anja Binckebanck; Harald Gschaidmeier; Dieter Hoelzer; Oliver G Ottmann
Journal:  Blood       Date:  2005-04-07       Impact factor: 22.113

2.  Ipilimumab for Patients with Relapse after Allogeneic Transplantation.

Authors:  Matthew S Davids; Haesook T Kim; Pavan Bachireddy; Caitlin Costello; Rebecca Liguori; Alexandra Savell; Alexander P Lukez; David Avigan; Yi-Bin Chen; Peter McSweeney; Nicole R LeBoeuf; Michael S Rooney; Michaela Bowden; Chensheng W Zhou; Scott R Granter; Jason L Hornick; Scott J Rodig; Masahiro Hirakawa; Mariano Severgnini; F Stephen Hodi; Catherine J Wu; Vincent T Ho; Corey Cutler; John Koreth; Edwin P Alyea; Joseph H Antin; Philippe Armand; Howard Streicher; Edward D Ball; Jerome Ritz; Asad Bashey; Robert J Soiffer
Journal:  N Engl J Med       Date:  2016-07-14       Impact factor: 91.245

3.  Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML).

Authors:  Oliver C Goodyear; Mike Dennis; Nadira Y Jilani; Justin Loke; Shamyla Siddique; Gordon Ryan; Jane Nunnick; Rahela Khanum; Manoj Raghavan; Mark Cook; John A Snowden; Mike Griffiths; Nigel Russell; John Yin; Charles Crawley; Gordon Cook; Paresh Vyas; Paul Moss; Ram Malladi; Charles F Craddock
Journal:  Blood       Date:  2012-01-10       Impact factor: 22.113

4.  Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.

Authors:  Bart L Scott; Marcelo C Pasquini; Brent R Logan; Juan Wu; Steven M Devine; David L Porter; Richard T Maziarz; Erica D Warlick; Hugo F Fernandez; Edwin P Alyea; Mehdi Hamadani; Asad Bashey; Sergio Giralt; Nancy L Geller; Eric Leifer; Jennifer Le-Rademacher; Adam M Mendizabal; Mary M Horowitz; H Joachim Deeg; Mitchell E Horwitz
Journal:  J Clin Oncol       Date:  2017-02-13       Impact factor: 44.544

5.  Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

Authors:  Christine E Ryan; Bita Sahaf; Aaron C Logan; Susan O'Brien; John C Byrd; Peter Hillmen; Jennifer R Brown; Martin J S Dyer; Anthony R Mato; Michael J Keating; Samantha Jaglowski; Fong Clow; Andrew R Rezvani; Lori Styles; Steven E Coutre; David B Miklos
Journal:  Blood       Date:  2016-11-01       Impact factor: 22.113

6.  Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation.

Authors:  R Coleman Lindsley; Wael Saber; Brenton G Mar; Robert Redd; Tao Wang; Michael D Haagenson; Peter V Grauman; Zhen-Huan Hu; Stephen R Spellman; Stephanie J Lee; Michael R Verneris; Katharine Hsu; Katharina Fleischhauer; Corey Cutler; Joseph H Antin; Donna Neuberg; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2017-02-09       Impact factor: 91.245

7.  Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism.

Authors:  Bruce R Blazar; Beatriz M Carreno; Angela Panoskaltsis-Mortari; Laura Carter; Yoshiko Iwai; Hideo Yagita; Hiroyuki Nishimura; Patricia A Taylor
Journal:  J Immunol       Date:  2003-08-01       Impact factor: 5.422

8.  Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant.

Authors:  Sarah L Sammons; Keith W Pratz; B Douglas Smith; Judith E Karp; Ashkan Emadi
Journal:  Am J Hematol       Date:  2014-06-23       Impact factor: 10.047

9.  Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.

Authors:  Eytan M Stein; Courtney D DiNardo; Daniel A Pollyea; Amir T Fathi; Gail J Roboz; Jessica K Altman; Richard M Stone; Daniel J DeAngelo; Ross L Levine; Ian W Flinn; Hagop M Kantarjian; Robert Collins; Manish R Patel; Arthur E Frankel; Anthony Stein; Mikkael A Sekeres; Ronan T Swords; Bruno C Medeiros; Christophe Willekens; Paresh Vyas; Alessandra Tosolini; Qiang Xu; Robert D Knight; Katharine E Yen; Sam Agresta; Stephane de Botton; Martin S Tallman
Journal:  Blood       Date:  2017-06-06       Impact factor: 25.476

10.  Tolerability and Clinical Activity of Post-Transplantation Azacitidine in Patients Allografted for Acute Myeloid Leukemia Treated on the RICAZA Trial.

Authors:  Charles Craddock; Nadira Jilani; Shamyla Siddique; Christina Yap; Josephine Khan; Sandeep Nagra; Janice Ward; Paul Ferguson; Peter Hazlewood; Richard Buka; Paresh Vyas; Oliver Goodyear; Eleni Tholouli; Charles Crawley; Nigel Russell; Jenny Byrne; Ram Malladi; John Snowden; Mike Dennis
Journal:  Biol Blood Marrow Transplant       Date:  2015-09-09       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.